SRx Health Solutions Inc.SRXH
▲ PositiveCapitalrelevance
Approved buyback and dividend, strong balance sheet with no debt.
Impact on assets 1
Biotech & Genomic Medicine
SRx Health Solutions Inc.SRx Health Solutions Inc.SRX Global Inc. reported a fiscal third-quarter GAAP loss of $0.36 per share on revenue of $3.4 million. Operating loss improved 63% year over year to $3.2 million, while net loss from continuing operations narrowed 40% year over year and 35% quarter over quarter to $4.1 million. Adjusted EBITDA loss improved 35% year over year to $1.6 million. The company ended the quarter with $36.7 million in cash, cash equivalents and restricted cash, $65.2 million in current assets, and $2.4 million in total liabilities with no debt outstanding. SRX Global also approved a 10 million share repurchase program and declared a one-time cash dividend of $0.05 per share, about $1.3 million in aggregate, to shareholders of record on July 22, 2026.
SRx Health Solutions Inc.Approved buyback and dividend, strong balance sheet with no debt.